Vir Biotechnology, Inc. cash flow to debt ratio of -209.61% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Vir Biotechnology, Inc.'s free cash flow has increased -12.57% from $-453.65M last year to $-396.61M, signaling increasing performance

Vir Biotechnology, Inc.'s debt to equity ratio is 0.12, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Vir Biotechnology, Inc.'s debt has increased relative to shareholder equity from 0.09 last year to 0.12 today, signaling weakened financials

Vir Biotechnology, Inc. has negative EBITDA, making leverage ratio unreliable

Vir Biotechnology, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Vir Biotechnology, Inc.'s profit margin has increased (-3.90%) in the last year from -703.40% to -675.96%, signaling increasing performance

Vir Biotechnology, Inc.'s short-term assets of $514.08M exceed its short-term liabilities of $92.81M

Vir Biotechnology, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Vir Biotechnology, Inc.'s return on equity of -53.31%, is lower than 15.00%, indicating bad performance

Vir Biotechnology, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Vir Biotechnology, Inc. had positive net income in only 2.00 out of 5 years, indicating unstable earnings

Vir Biotechnology, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Vir Biotechnology, Inc. has negative free cash flow, indicating cash burn

Vir Biotechnology, Inc.'s yearly earnings has increased -16.09% since last year from $-521.96M to $-437.99M, signaling increasing performance

Vir Biotechnology, Inc.'s yearly revenue has decreased -7.61% since last year from $74.20M to $68.56M, signaling decreasing performance

ROIC -48.04% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Vir Biotechnology, Inc.'s 3-year revenue CAGR of -65.12% is negative, indicating declining revenue over the past 3 years

Vir Biotechnology, Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

Vir Biotechnology, Inc. had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity

Vir Biotechnology, Inc. has insufficient data to evaluate this check.

Vir Biotechnology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Vir Biotechnology, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Vir Biotechnology, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Vir Biotechnology, Inc. is overvalued relative to its fair value price of -24.75 based on Earnings Fair Value model

Vir Biotechnology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Vir Biotechnology, Inc. has a price-to-book ratio of 1.72x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Vir Biotechnology, Inc. has a price-to-sales ratio of 21.35x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue